Amgen Inc. (NASDAQ:AMGN) SVP Nancy A. Grygiel Sells 2,117 Shares of Stock

Amgen Inc. (NASDAQ:AMGN) SVP Nancy A. Grygiel sold 2,117 shares of Amgen stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $313.09, for a total transaction of $662,811.53. Following the sale, the senior vice president now owns 9,883 shares of the company’s stock, valued at $3,094,268.47. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Amgen Price Performance

Shares of Amgen stock opened at $311.29 on Friday. The business has a 50 day simple moving average of $274.51 and a two-hundred day simple moving average of $281.33. The company has a debt-to-equity ratio of 10.14, a current ratio of 1.65 and a quick ratio of 1.13. The stock has a market capitalization of $166.97 billion, a P/E ratio of 24.92, a PEG ratio of 2.68 and a beta of 0.60. Amgen Inc. has a 12 month low of $211.71 and a 12 month high of $329.72.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Thursday, May 2nd. The medical research company reported $3.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.76 by $0.20. Amgen had a return on equity of 154.27% and a net margin of 23.83%. The business had revenue of $7.45 billion during the quarter, compared to analyst estimates of $7.45 billion. During the same period in the prior year, the business earned $3.98 earnings per share. The business’s revenue was up 22.0% compared to the same quarter last year. As a group, analysts predict that Amgen Inc. will post 19.43 EPS for the current fiscal year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 17th will be paid a $2.25 dividend. This represents a $9.00 dividend on an annualized basis and a dividend yield of 2.89%. The ex-dividend date is Thursday, May 16th. Amgen’s dividend payout ratio (DPR) is 72.06%.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. Truist Financial restated a “buy” rating and issued a $320.00 target price on shares of Amgen in a research note on Friday, April 12th. The Goldman Sachs Group lifted their target price on Amgen from $313.00 to $350.00 and gave the stock a “buy” rating in a report on Wednesday, February 7th. BMO Capital Markets increased their price target on shares of Amgen from $336.00 to $355.00 and gave the stock an “outperform” rating in a report on Friday. TD Cowen reduced their price target on shares of Amgen from $370.00 to $360.00 and set a “buy” rating for the company in a research report on Wednesday, April 17th. Finally, Barclays raised shares of Amgen from an “underweight” rating to an “equal weight” rating and upped their price objective for the company from $230.00 to $300.00 in a report on Friday. Ten research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $305.05.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. OFI Invest Asset Management purchased a new position in Amgen during the 3rd quarter valued at about $26,000. Briaud Financial Planning Inc acquired a new stake in Amgen during the 3rd quarter worth approximately $26,000. Horizon Financial Services LLC purchased a new position in Amgen in the 1st quarter valued at approximately $28,000. BOK Financial Private Wealth Inc. purchased a new stake in shares of Amgen during the fourth quarter worth $29,000. Finally, United Community Bank purchased a new stake in Amgen during the 4th quarter worth about $29,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.